MicroRNA 101-3p and microRNA 23-3p regulate major arrhythmia risk genes, including HCN4 and KCN3, demonstrating their potential as therapeutic targets for managing cardiac arrhythmia.
MicroRNA 101-3p and microRNA 23-3p were identified as potential therapeutic targets and diagnostic markers for cardiac arrhythmia through advanced genomic exploration.
Absolute Event Rate: 0% vs 0%
Abstract Background Cardiac arrhythmia is one of the major global health burdens being responsible for leading to stroke and heart failure. Managing this high risk disease at an earlier level remained a point of concern for clinicians and researchers 1, 2. Purpose Our study is focused in identifying such endogenous transcription regulatory microRNAs (miRNAs) that possess the potential to target earlier molecular risks of the arrhythmia including hypertension and renal burden. Methods Hub genes prediction of microRNAs and their potential target genes from the microarray data sets, microRNAs targets prediction on 8mer seed sequences matching bases from miRBAse, and targetscan, Genes functional enrichment analysis, PPI network development, cohort validation of miRNAs and their respective target genes in hub modular form. Results Screening from overlapped expression of arrhythmia causative genes including sinoatrial response regulators, cardiac cells membrane polarity regulators, axis of cardio-nervous regulators and hypertension regulators elucidated the role of set of modulatory endogenous gene silencing microRNAs. Micro RNA 101-3p and microRNA 23-3p with significant risk nexus genes management including ZFH X3, HCN4, KCN3, ADR B1, SOX 6, MED and HSP 9 etc involving management of beta adrenergic receptors activity, sodium importer activity, BMP receptor activity, postsynaptic membrane potential regulators, cation channels and transporters regulation, and dopamine sodium transporter etc. Conclusion These microRNAs with potential of simultaneous regulation of major arrhythmia risks associated genes at the basal molecular level propose their future significance in therapeutic and advanced diagnostic modeling.
Murtaza et al. (Sun,) reported a other. MicroRNA 101-3p and microRNA 23-3p regulate major arrhythmia risk genes, including HCN4 and KCN3, demonstrating their potential as therapeutic targets for managing cardiac arrhythmia.